McKesson Corporation ($MCK) Stock Forecast: Down 5.2% Today

What is McKesson Corporation?

McKesson Corporation (MCK) is a healthcare company specializing in pharmaceuticals and medical supplies. It operates across different segments, which include U.S. Pharmaceutical, Medical Surgical Solutions, and Specialty Solutions.

Why is McKesson Corporation going down?

MCK stock is down 5.2% on Feb 6, 2025 14:44

• Following the release of its Q3 earnings report, McKesson's stock faced a downturn due to missing expectations and a decrease in gross margin, particularly in the Medical Surgical Solutions segment.
• The acquisition of PRISM Vision Holdings was viewed positively as a move to bolster McKesson's specialty care capabilities and leadership in eye health solutions. However, this development did not have an immediate impact on the stock price.
• Despite anticipated strong performance in the U.S. Pharmaceutical and Specialty Solutions segment, McKesson's stock performed worse than the overall market, reflecting investor apprehensions.
• The market response to McKesson's Q3 earnings indicates that investors may have been more focused on the lower sales and margin contraction in the Medical Surgical Solutions segment, overshadowing growth in other areas of the company.

MCK Price Chart

MCK Technical Analysis

MCK News

MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts

McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

https://www.zacks.com/stock/news/2410723/mck-stock-down-on-q3-earnings-sales-miss-gross-margin-contracts

McKesson Stock May Rise With PRISM Vision Holdings Acquisition

MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.

https://www.zacks.com/stock/news/2410341/mckesson-stock-may-rise-with-prism-vision-holdings-acquisition

MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?

McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

https://www.zacks.com/stock/news/2408933/mck-stock-before-q3-earnings-a-smart-buy-or-risky-investment

McKesson ( MCK ) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, McKesson (MCK) stood at $594.75, denoting a -1.63% change from the preceding trading day.

https://www.zacks.com/stock/news/2407848/mckesson-mck-declines-more-than-market-some-information-for-investors

Gear Up for McKesson ( MCK ) Q3 Earnings: Wall Street Estimates for Key Metrics

Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

https://www.zacks.com/stock/news/2407473/gear-up-for-mckesson-mck-q3-earnings-wall-street-estimates-for-key-metrics

Trending Today

Sei ($SEI) Crypto Forecast: Up 5.9% Today

Cardano ($ADA) Crypto Forecast: Down 5.6% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.7% Today

Movement ($MOVE) Crypto Forecast: Down 6.4% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 8.8% Today

dogwifhat ($WIF) Crypto Forecast: Down 5.2% Today

Ethereum Classic ($ETC) Crypto Forecast: Down 5.4% Today

Peanut Squirrel ($PNUT) Crypto Forecast: Up 6.6% Today

Mantle ($MNT) Crypto Forecast: Down 11.1% Today

Litecoin ($LTC) Crypto Forecast: Down 6.4% Today

McKesson Corporation Price History

13.00.2025 - MCK Stock was up 1.3%

• The bullish movement in MCK likely stems from positive sentiment in the pharmaceutical sector, potentially fueled by robust earnings or promising drug advancements.
• This upward trend in MCK may also be buoyed by general market positivity, as evidenced by the strong performance of similar companies such as PDEX.
• Investors could be perceiving MCK as a secure investment option, resulting in heightened buying activity and an upward push in the stock price.

05.08.2024 - MCK Stock was down 8.3%

• The bearish movement in McKesson's stock today could be attributed to the recent $300 million opioid settlement that the company, along with other drug distributors, has agreed to pay to resolve claims from health insurers and benefit plans. This settlement could have negative financial implications for McKesson in the short term.
• Bearish options activity observed by investors on McKesson's stock further indicates a lack of confidence or pessimistic sentiment surrounding the company's future performance.
• The market may be reacting to the uncertainty and potential financial impact of the settlement on McKesson's profitability and reputation, leading to a sell-off of the stock by investors anticipating a downturn in the company's prospects.
• Overall, the combination of the negative news regarding the opioid settlement and the bearish options activity likely contributed to the significant bearish movement in McKesson's stock today.

05.08.2024 - MCK Stock was down 6.2%

• McKesson and other leading drug distributors recently reached a substantial $300 million settlement with health insurers and benefit plans related to the opioid epidemic.
• The news of the opioid settlement likely impacted investor sentiment and contributed to the drop in McKesson's stock price.
• Investors are showing apprehension regarding the financial implications of the settlement on McKesson's future profits and possible regulatory implications within the pharmaceutical distribution sector.
• The market response suggests that investors are considering the legal and financial risks associated with McKesson's involvement in the opioid crisis, leading to the downward movement in the stock.

14.00.2025 - MCK Stock was up 0.6%

• McKesson exhibited significant bullish momentum today, surpassing market benchmarks.
• The company has consistently outperformed the market, delivering an average yearly return of 16.04% over the past 15 years.
• McKesson's robust position in the healthcare field and its adeptness in responding to market dynamics likely underlie its strong performance.
• Investor optimism regarding McKesson's future growth potential appears to be driving the bullish stock movement.

24.08.2024 - MCK Stock was down 6.5%

• McKesson's stock decreased by -0.68% today, going against the overall market direction.
• Despite increased options activity suggesting optimism among investors, the stock did not perform positively.
• Despite strong collaborations and Biologics strength, external market conditions could have impacted the stock's decline.
• Analyst downgrades and general market sentiment likely played a role in the stock's bearish movement.

15.09.2024 - MCK Stock was up 2.3%

• Over the past 5 years, McKesson (MCK) has delivered an impressive average annual return of 29.57%, surpassing market performance by a considerable margin.
• The closing price of McKesson (MCK) stood at $502.12, reflecting a +1.42% change compared to the previous trading session.
• The robust bullish trend in McKesson's stock today may be linked to its consistent market outperformance, signaling investor trust in the company's growth prospects and financial health.

07.10.2024 - MCK Stock was up 12.4%

• Recent positive developments contributed to McKesson's stock rise:
• Increased options activity indicated investor optimism about the company's future.
• Analysts raised their forecasts post a favorable earnings report, emphasizing the company's strong financial results.
• McKesson exceeded Q2 earnings and revenue expectations, further boosting investor confidence.
• The company's long-term market outperformance, demonstrated by a significant return on investment spanning two decades, attracted more investors, leading to a rise in stock value.

07.10.2024 - MCK Stock was up 9.4%

• McKesson reported better-than-expected second-quarter financial results, with earnings of $7.07 per share and sales of $93.70 billion, beating analyst estimates. This positive earnings report likely contributed to the bullish movement.
• Analysts have turned bullish on McKesson, with upgrades and increased price targets following the upbeat earnings report. This positive sentiment from analysts could have further boosted the stock.
• The company's consistent outperformance over the past 20 years, with an average annual return of 15.46%, has likely attracted investors looking for long-term growth opportunities.
• Expectations for solid performance in the U.S. Pharmaceutical and Specialty Solutions segment in the upcoming earnings report may have also fueled investor optimism and contributed to the bullish movement in the stock.

07.10.2024 - MCK Stock was up 11.0%

• Today, McKesson's strong bullish movement is supported by several factors:
• Increased options activity and positive investor sentiment suggest confidence in the company's future.
• Second-quarter fiscal 2025 results surpassing expectations, especially in the U.S. Pharmaceutical segment, have contributed to a favorable market outlook.
• Analysts revising their forecasts upward and expressing optimism about McKesson post-earnings have further encouraged investor confidence.
• In conclusion, robust earnings performance and a positive outlook for McKesson have driven the stock's bullish trend today.

06.01.2025 - MCK Stock was down 5.2%

• Following the release of its Q3 earnings report, McKesson's stock faced a downturn due to missing expectations and a decrease in gross margin, particularly in the Medical Surgical Solutions segment.
• The acquisition of PRISM Vision Holdings was viewed positively as a move to bolster McKesson's specialty care capabilities and leadership in eye health solutions. However, this development did not have an immediate impact on the stock price.
• Despite anticipated strong performance in the U.S. Pharmaceutical and Specialty Solutions segment, McKesson's stock performed worse than the overall market, reflecting investor apprehensions.
• The market response to McKesson's Q3 earnings indicates that investors may have been more focused on the lower sales and margin contraction in the Medical Surgical Solutions segment, overshadowing growth in other areas of the company.

08.07.2024 - MCK Stock was down 12.1%

• Supply and demand issues for weight-loss drugs led to a bearish movement for McKesson, impacting service sales negatively.
• Analysts' expectations were not met as the company's revenue forecast for the year fell short, resulting in a decline in stock price.
• Despite weak sales and core earnings miss, McKesson saw its stock target raised by Mizuho, hinting at optimism for the company's future performance.
• McKesson's bearish market movement today was influenced by supply chain challenges, a revenue forecast miss, and mixed analyst sentiment.

08.07.2024 - MCK Stock was down 12.5%

• The company witnessed a significant decline in its stock price today following weaker than anticipated first-quarter sales results.
• McKesson (MCK) outperformed earnings expectations and displayed revenue growth in the U.S. Pharmaceutical segment. However, reduced COVID-related sales adversely affected overall performance, particularly in the Medical Surgical Solutions segment.
• Despite falling short of core earnings expectations, a stock target increase by Mizuho could suggest some positive outlook for the company's future.
• The lower-than-expected quarterly revenue, especially in the U.S. pharmaceutical segment, where specialty drug sales for complex conditions declined, likely influenced the negative market trend.